Category: Accesswire

Regulated entities can streamline stablecoin operations – permissioned or permissionless – using ALT5 Sigma’s Crypto-as-a-Service platform, fully compatible with proprietary and third-party assets.

LAS VEGAS, NV / ACCESS Newswire / June 30, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1), a leading provider of Crypto-as-a-Service infrastructure, has launched a comprehensive stablecoin management solution for U.S. institutions. Designed for regulated entities, the platform enables seamless integration, utilization, and oversight of stablecoins-regardless of the issuing entity or blockchain protocol. Whether managing proprietary tokens or leveraging market leaders, institutions can operationalize, monitor, and scale stablecoin use through ALT5 Sigma’s infrastructure. Integration with existing workflows and systems is supported via robust APIs.

“Stablecoins represent a critical bridge between traditional finance and the blockchain economy,” said Ron Pitters, Chief Operating Officer of ALT5 Sigma Corporation. “We’re focused on removing operational barriers so institutions can maximize the utility of stablecoins they already trust-whether issued in-house or sourced externally. By integrating stablecoins into enterprise systems, we enable real-time payments, automated settlements, and streamlined treasury functions-without requiring custom blockchain development.”

ALT5 Sigma’s infrastructure supports both permissioned and permissionless stablecoins, enabling institutions to:

• Integrate stablecoins into core operations, regardless of the blockchain or issuance model

• Manage risk, compliance, and wallet infrastructure through built-in KYC/AML and monitoring tools

• Connect to internal systems via APIs, including treasury, ERP, CRM, and banking platforms

• Enable programmable flows, such as recurring disbursements, settlement automation, and cross-border transfers

Seamless Support for Industry-Leading Stablecoins

The ALT5 Sigma platform already supports the world’s largest and most liquid stablecoins, including Tether (USDT), USD Coin (USDC), World Liberty Financial (USD1), EURC (EURC), and many others.

A Regulatory Tailwind: The Transformational Impact of the GENIUS Act

The GENIUS Act (Guaranteed and Enhanced National Interest in the United States Stablecoins Act), recently passed by the U.S. Senate, marks a pivotal moment for the regulated adoption of digital assets. As it heads to the House of Representatives, the Act outlines clear requirements for 1:1 reserves in high‑quality liquid assets, licensing for issuers exceeding $10 billion in circulation, monthly audits and transparency reports, and robust anti‑money laundering provisions.

ALT5 Sigma’s stablecoin framework is fully aligned with these emerging standards, ensuring compliance and operational integrity from day one.

ALT5 Sigma stands ready to help institutions swiftly deploy compliant stablecoins-new or existing-and capitalize this momentum to modernize their payment and treasury operations.

For additional information, please contact: sales@alt5sigma.com

About ALT5 Sigma Corporation

ALT5 Sigma Corporation (NASDAQ: ALTS) (FRA: 5AR1) is a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. ALT5 has been a constituent of the Russell Microcap Index since June 28, 2024.

Founded in 2018, ALT5 Sigma, Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) enables the migration to a new global financial paradigm through its suite of blockchain infrastructure technologies. ALT5 Sigma, Inc., through its subsidiaries, offers two main platforms: “ALT5 Pay” and “ALT5 Prime.” The company has processed over $5 billion USD in cryptocurrency transactions since inception.

ALT5 Pay is an award-winning cryptocurrency payment gateway that enables registered and approved global merchants to accept and make cryptocurrency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency(s) automatically or to receive their payment in digital assets.

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named “ALT5 Pro” that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime’s FIX API, as well as through Broadridge Financial Solutions’ NYFIX gateway for approved customers.

The Company is also advancing the separation of its biotech business, which will continue under “Alyea Therapeutics Corporation.” Through its biotech activities, the Company is focused on bringing to market drugs with non-addictive pain-relieving properties to treat conditions that cause chronic or severe pain. Our patented product, a novel formulation of low-dose naltrexone (JAN123), is being initially developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. The FDA has granted Jan123 Orphan Drug Designation for treatment of CRPS.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5’s platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5’s services, and technology challenges for future growth or expansion. This press release also may contain statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as “continue”, “expect”, “intend”, “will”, “hope”, “should”, “would”, “may”, “potential”, and other similar expressions. Such statements reflect the Company‘s current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

Many factors could cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release. Such factors could include, among others, those detailed in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the sections entitled “Risk Factors” in the Company’s filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Media/Investor Relations Contact

IR@alt5sigma.com
1-800-400-2247

SOURCE: ALT5 Sigma Corp

View the original press release on ACCESS Newswire

A highly reputable national and multinational customer base across eight market segments reinforces the quality of 5E’s boric acid and reflects changing global supply-demand dynamics

HESPERIA, CA / ACCESS Newswire / June 30, 2025 / 5E Advanced Materials, Inc. (Nasdaq:FEAM)(ASX:5EA), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas (Fort Cady) Complex, announced today that 14 customers have successfully qualified 5E’s boric-acid product. Additional customers have requested product or are in advanced phases of the testing process.

Customers that have qualified our product represent a diverse group of industries and market segments such as specialty glass, textile fiberglass, ceramics, insulation, agriculture, defense and chemicals. Testing programs to date have included laboratory evaluation, field trials, and truckload-scale shipments. This progress supports the Company’s strategy to build a multi-market customer base across multiple high value sectors.

“We view 2025 as a pivotal year of inflection whereby the boron market will begin to see a deficit in supply, and reliable product in the boron market is expected to become scarce and in short supply. This has been reinforced by the number of customers that have successfully qualified our product. We continue to see strong interest from customers seeking high-purity, U.S. based boron supply and are encouraged by our qualification progress to date,” said Paul Weibel, Chief Executive Officer of 5E Advanced Materials. “These customer qualifications underscore our commitment to delivering a secure, U.S.-based source of high-purity boron supply for industries that are central to U.S. priorities and bolster the U.S. industrial base. Of significant importance, I am incredibly proud of 5E’s team for successfully passing three LCD glass manufacturers initial product testing protocol as this market segment has some of the most difficult quality requirements across the globe.”

The Company believes this progress highlights its continued momentum toward building commercial relationships and advancing its operational and strategic objectives.

About 5E Advanced Materials, Inc.

5E Advanced Materials, Inc. (Nasdaq: FEAM) (ASX:5EA) is focused on becoming a vertically integrated global leader and supplier of boron specialty and advanced materials, complemented by lithium co-product production. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, food and domestic security. Boron and lithium products will target applications in the fields of electric transportation, clean energy infrastructure, such as solar and wind power, fertilizers, and domestic security. The business strategy and objectives are to develop capabilities ranging from upstream extraction and product sales of boric acid, lithium carbonate and potentially other co-products, to downstream boron advanced material processing and development. The business is based on our large domestic boron and lithium resource, which is located in Southern California and designated as Critical Infrastructure by the Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical fact included in this press release regarding the Company’s business strategy, plans, goals, and objectives, the ongoing onboarding and qualification process for the Company’s product, anticipated changes in demand for boron, and the Company’s ability to deliver a secure, U.S.-based source of high-purity boron supply for industries that are central to U.S. priorities and bolster the U.S. industrial base, are forward-looking statements. When used in this press release, the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intent,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on the Company’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. We caution you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond our control, incident to the extraction of the critical materials we intend to produce and advanced materials production and development. These risks include, but are not limited to: our ultimate ability to satisfy all customer qualification criteria and achieve commercial offtake agreements, our limited operating history in the borates and lithium industries and no revenue from our proposed extraction operations at our properties; our need for substantial additional financing to execute our business plan and our ability to access capital and the financial markets; our status as an exploration stage company dependent on a single project with no known Regulation S-K 1300 mineral reserves and the inherent uncertainty in estimates of mineral resources; our lack of history in mineral production and the significant risks associated with achieving our business strategies, including our downstream processing ambitions; our incurrence of significant net operating losses to date and plans to incur continued losses for the foreseeable future; risks and uncertainties relating to the development of the Fort Cady project, including our ability to timely and successfully complete our proposed Commercial Scale Boron Facility; our ability to obtain, maintain and renew required governmental permits for our development activities, including satisfying all mandated conditions to any such permits; the implementation of and expected benefits from certain reduced spending measures; the impact of changes in U.S. trade policies and the imposition of tariffs; and other risks and uncertainties set forth in our filings with the U.S. Securities and Exchange Commission from time to time. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statements. These risks are not exhaustive, and the information in this press release may be subject to additional risks. No representation or warranty (express or implied) is made as to, and no reliance should be place on, any information, including projections, estimates, targets, and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions, or misstatements contained herein. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as to the date of this press release.

For additional information regarding these various factors, you should carefully review the risk factors and other disclosures in the Company’s Form 10-K filed on September 9, 2024, as updated by the Company’s Form 10-Q filed on May 15, 2025, and subsequent filings with the U.S. Securities and Exchange Commission throughout the year, as well as in its filings under the Australian Securities Exchange. Any forward-looking statements are given only as of the date hereof. Except as required by law, 5E expressly disclaims any obligation to update or revise any such forward-looking statements. Additionally, 5E undertakes no obligation to comment on third party analyses or statements regarding 5E’s actual or expected financial or operating results or its securities.

For further information contact:

Michael MacMillan or Paola Ashton
PRA Communications
team@pracommunications.com
Ph: +1 (604) 681-1407

SOURCE: 5E Advanced Materials, Inc.

View the original press release on ACCESS Newswire

Clear Start Tax Explains Who the IRS Actually Sends to Jail – and Why Most Taxpayers Don’t Need to Fear Prison Over Back Taxes

IRVINE, CA / ACCESS Newswire / June 30, 2025 / With IRS enforcement ramping up in 2025, many Americans are asking a frightening question: “Can I go to jail for back taxes?” According to Clear Start Tax, the answer depends on one critical factor – intent. While jail time is rare, it becomes a risk in cases involving fraud, evasion, or willful concealment.

“People hear horror stories about IRS arrests and panic unnecessarily,” said the Head of Client Solutions at Clear Start Tax. “But the average taxpayer who’s behind on payments or hasn’t filed simply needs to resolve the issue, not fear handcuffs.”

When Jail Time Becomes a Real Possibility

Not all tax problems lead to prison – in fact, most don’t. But there are specific situations where the IRS may pursue criminal enforcement instead of civil penalties. Clear Start Tax outlines the key scenarios where jail time becomes a real risk:

• Criminal Tax Evasion – Intentionally underreporting income, falsifying records, or hiding money in unreported accounts can lead to federal charges and prison sentences.

• Fraudulent Returns – Filing returns with knowingly false information – including fake deductions or dependents – is considered fraud.

• Identity or Refund Theft – Using someone else’s information or filing fake returns to claim a refund is a federal crime.

• Repeated, Willful Non-Filing – Ignoring IRS notices and failing to file taxes for several years may be treated as willful neglect.

“The IRS pursues criminal charges only when someone knowingly breaks the law,” added the Head of Client Solutions. “But the vast majority of people with tax debt fall under civil enforcement, which means the IRS wants compliance, not incarceration.”

What Happens to Honest Taxpayers Who Owe?

Most people with unpaid taxes or late filings fall under civil enforcement, not criminal investigation. While jail isn’t on the table, there are still serious consequences for ignoring IRS notices. Here are some of the most common consequences faced by taxpayers who fall behind:

• IRS notices and penalties

• Bank levies or wage garnishments

• Tax liens

• Lost refunds or passport restrictions

But all of these are part of the civil process, and can be resolved without legal consequences when addressed early.

Don’t Panic – Get Help Instead

Filing late or owing taxes isn’t a crime, but ignoring the issue can lead to bigger problems. Clear Start Tax works with clients nationwide to resolve tax debt, file overdue returns, and set up realistic, affordable solutions that stop IRS enforcement before it escalates.

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

How Clear Start Tax Helps Taxpayers at Risk

Whether you’re behind on filings, facing collections, or simply unsure what the IRS will do next, Clear Start Tax offers expert support from start to finish. Their services include:

• Filing back tax returns accurately

• Reviewing IRS transcripts and notices

• Preventing or releasing wage garnishments

• Applying for Offers in Compromise or hardship status

• Managing communication with the IRS from start to finish

“Falling behind on taxes can leave people feeling stuck or overwhelmed,” said the Head of Client Solutions at Clear Start Tax. “We help them move forward with clarity, confidence, and the right legal steps.”

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss

MIAMI, FLORIDA / ACCESS Newswire / June 30, 2025 / MIRA (NASDAQ:MIRA) today announced new animal study results from SKNY-1, a next-generation oral therapeutic under definitive agreement for acquisition. In a zebrafish model that mimics human obesity and craving behaviors, SKNY-1 demonstrated weight loss, suppression of appetite and craving for high-calorie diets, and reversal of nicotine-seeking behavior-all achieved within six days of oral treatment.

SKNY-1 is being developed as an oral alternative to GLP-1 injectables, which are often limited by nausea, GI discomfort, injection reaction, and growing concerns around muscle loss. Unlike GLP-1s, which reduce both fat and lean mass, SKNY-1 demonstrated significant weight loss with preserved muscle. It was specifically designed to minimize engagement with central nervous system pathways implicated in the psychiatric side effects observed in some smoking cessation therapies and first-generation CB1-targeting weight-loss drugs. The data support SKNY-1’s potential as a differentiated oral therapy addressing two of the world’s leading causes of preventable death.

The study was conducted in an obesity and craving model in Ob42 Strain-mc4r (G894C) mutated zebrafish following six days of oral treatment with two doses of SKNY-1 and was compared to normal controls.

Key Results

Weight Loss and Muscle Preservation:
SKNY-1 reduced body weight by approximately 30% after just six days of oral treatment. Treated animals ended up weighing about 10% less than healthy controls. Importantly, this weight loss was not accompanied by muscle density changes-suggesting SKNY-1 helps burn fat while preserving lean body mass.

Metabolic Activity and Ventilation Rate:
Treated animals showed an increase in breathing rate, which is a reliable signal that their metabolism was speeding up. This aligns with the observed weight loss and suggests that SKNY-1 helps the body burn more energy.

Liver and Lipid Profile Improvements:
In untreated obese animals, fat buildup in the liver was about 50% higher than normal. SKNY-1 reversed this buildup, bringing liver fat back to healthy levels. At the same time, cholesterol levels-including LDL (‘bad’ cholesterol) and HDL (‘good’ cholesterol)-also returned to normal, without affecting fat levels in the blood. This points to improved fat processing without disrupting the body’s overall metabolic balance.

Appetite, Craving, and Compulsive Eating:
Obese animals were eating 2-3 times more high-calorie food than normal. SKNY-1 dose-dependently reduced this behavior-high-dose animals ate less than healthy controls. The drug also made the animals less likely to pursue food in stressful environments and reduced obsessive food-seeking in tests designed to measure craving.

Nicotine Craving and Compulsivity:
SKNY-1 significantly reduced the desire to seek out and consume nicotine. Treated animals were less willing to pursue nicotine even in stressful conditions, and they no longer showed a preference for environments linked to nicotine rewards. At the high dose, their behavior matched that of healthy animals with no nicotine craving.

Neurohormonal Balance:
Obese animals had extremely high levels of leptin (a hunger-regulating hormone) and unusually low levels of ghrelin (the ‘hunger signal’). This imbalance often leads to constant hunger and poor appetite control. SKNY-1 normalized both hormones, improving the body’s ability to regulate hunger and energy use.

Brain Dopamine Regulation:
Obese animals had too much dopamine in the brain, likely tied to increased reward and cravings. SKNY-1 reduced these dopamine levels-but only at the lower dose. The high dose did not affect dopamine, suggesting the drug can reduce craving without overstimulating the brain.

“Within just six days, we saw robust behavioral, hormonal and metabolic changes, including weight loss, improved fat metabolism, and reversal of craving-like behaviors,” said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. “These results highlight SKNY-1’s potential to address both obesity and nicotine addiction through unique and safe pathways.”

A Differentiated Approach to Two Major Markets

Current weight-loss therapies like semaglutide and tirzepatide are effective but limited by gastrointestinal side effects, injectable administration, and loss of lean mass. Smoking cessation treatments such as varenicline and bupropion carry psychiatric warnings and offer modest long-term quit rates.

SKNY-1 was designed to overcome these limitations. It selectively modulates CB1 receptors by blocking β-arrestin signaling-associated with cravings and compulsive behavior-while preserving G-protein signaling, which supports emotional and cognitive stability. The compound also activates CB2 receptors and mildly inhibits MAO-B without affecting MAO-A, supporting a favorable safety and tolerability profile.

“These results position SKNY-1 as a potentially disruptive oral treatment,” said Erez Aminov, CEO of MIRA. “Its ability to reduce body mass, suppress cravings, and preserve muscle-all through oral administration-makes it a compelling therapeutic candidate as we move toward closing the acquisition and preparing for IND-enabling studies.”

The Company believes these findings further support the advancement of SKNY-1 toward Investigational New Drug (IND)-enabling studies. With obesity and smoking representing two of the leading causes of preventable death-and a combined global market opportunity exceeding $200 billion-MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending completion of the acquisition of SKNY Pharmaceuticals, Inc.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as anxiety, cognitive decline, neuropathic pain, obesity, and addiction.

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older

CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company’s seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%.

“Today’s strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults. The severity of this past flu season underscores the need for more effective vaccines,” said Stéphane Bancel, Chief Executive Officer of Moderna. “An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines.”

In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. ^[1]

According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. ^[2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work. ^[3]

P304 ( NCT06602024 ) is a Phase 3, randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months.

Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. ^[4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported. There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest.

Moderna plans to present these data at an upcoming medical conference and submit for peer-reviewed publication. The Company will engage with regulators on filing submissions for mRNA-1010.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.


Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s engagement with regulators on filing submissions for its standalone flu vaccine candidate; and the efficacy, safety and tolerability of mRNA-1010. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov . Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:

Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:

Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

IRON MOUNTAIN, MI / ACCESS Newswire / June 30, 2025 / CCI Systems Inc. is pleased to announce that it has acquired Total Site Services, a leading provider of Tower site acquisition, engineering design, and construction management services. This strategic acquisition strengthens CCI Systems’ position in the wireless industry, enhancing our capabilities and accelerating our market expansion.

We are excited to welcome the talented Total Site Services team’s integration into CCI Systems, a 100% employee-owned company. The expertise and experience of this acquisition strengthens our company’s team of skilled professionals to provide an even greater value, meeting the diverse needs of our clients and driving innovation. This move aligns with our long-term growth strategy and commitment to delivering comprehensive solutions across various sectors.

Brian Horton, the former CEO of Total Site Services, stated, “Joining forces with CCI Systems marks an exciting new chapter for our team at Total Site Services. We’ve built a strong foundation in the wireless industry, and this partnership allows us to scale our impact while continuing to deliver the high-quality service our clients expect. We’re proud to become part of an employee-owned company that shares our values and vision for the future.”

Troy Knuckles, Executive Vice President and COO at CCI Systems, stated, “This acquisition represents a significant milestone for CCI Systems as we continue to further diversify our service offerings. We are confident that the combined strengths of CCI Systems and Total Site Services will create new opportunities for growth and success for our customers. Our commitment to excellence and customer satisfaction remains unwavering as we embark on this exciting journey together.”

About CCI Systems Inc.

For the past 60 years, CCI Systems has remained an industry-leading provider of innovative service solutions in the broadband telecommunications sector. With a focus on delivering exceptional service combined with utilizing a range of cutting-edge technology, CCI Systems has built a reputation for excellence and reliability. Our comprehensive suite of services includes consulting and due diligence, network planning and design, full suite engineering, technical field services, construction management, cybersecurity and other network sustainability services, ensuring our clients stay connected and competitive in today’s fast-paced digital landscape.

About Total Site Services

Total Site Services is a premier provider of wireless telecom site acquisition services, engineering design, and construction management. With a team of experienced professionals, Total Site Services has successfully delivered projects across various industries, including telecom, commercial, civil, government, and institutional sectors. Their commitment to quality and customer satisfaction has made them a trusted partner for clients seeking reliable and efficient project management solutions.

For more information, please contact:

Dillon Records
Director of Marketing
CCI Systems Inc.
Phone: (800) 338-9299
Email: info@ccisystems.com
Website: www.ccisystems.com

SOURCE: CCI Systems Inc.

View the original press release on ACCESS Newswire

PALM BEACH GARDENS, FL / ACCESS Newswire / June 30, 2025 / Eagle Football Holdings Limited today confirmed its support of leadership changes which shall occur at its subsidiary Eagle Football Group (France) and Olympique Lyonnais.

John Textor, Chairman and majority owner of Eagle Football Holdings, acting in his capacity as the sole director, and on behalf of the sole shareholder, of Olympique Lyonnais, today appointed Michael Gerlinger to the position of Director General (CEO), and Michele Kang to the position of Chair and President. Mr. Textor has resigned from his leadership positions at Olympique Lyonnais, in favor of the appointment of Ms. Kang and Mr. Gerlinger.

Michele Kang, who is also a leading shareholder of Eagle Football Holdings, has served on the OL board since 2023, has been appointed Chair and President. She will take an active role in supporting OL’s executive management, including spearheading the club’s appeal process with the DNCG.

Michael Gerlinger, currently Chief Sports Officer of Eagle Football, has been appointed Director General of Olympique Lyonnais. A widely respected figure in European football administration, Michael brings over two decades of experience in governance, regulatory affairs and sporting operations.

Mr. Textor remains Chairman, CEO and majority owner of Eagle Football Holdings (UK), principal owner of SAF Botafogo (Brazil), Olympique Lyonnais (France), Crystal Palace FC (England) and Daring Brussels (Belgium). In terms of day-to-day responsibilities, he will now re-focus his attention on SAF Botafogo, Daring Brussels and Eagle’s Football club acquisition strategies in the UK.

Chairman and CEO, John Textor said:

“I am extremely proud of the global sporting successes of Eagle Football, with historic championships, cup wins, and tournament qualifications in Brazil, France and England, but it’s clear that we must make changes in our management approach, if we expect to be as effective off-the-pitch, as we are on-the-pitch.”

Regarding Olympique Lyonnais, “Each of our clubs and communities deserve leadership, with a strong local presence, and the acumen to overcome both the sporting and the non-sporting challenges that we face. It’s obvious to everyone that Michele is a perfect choice to lead OL, and I am thrilled for our community that she has accepted the job.”

He continued, “On a personal level, I am truly looking forward to the reduction of my day-to-day management responsibilities in Europe, so I can focus on markets where we have the full freedom to run our football clubs…to invest, innovate, grow and compete. OL in great hands with Michele, and I will focus on Botafogo, Daring Brussels and our next club in England.”

About Eagle Football Holdings Limited

INSPIRED BY FOOTBALL, DRIVEN BY FOOTBALL…MUCH MORE THAN FOOTBALL

Eagle Football is a sports, entertainment and technology company that engages with a global audience through its portfolio of interests in iconic football clubs and related assets around the world. Eagle Football is the leading shareholder of SAF Botafogo (reigning champion of Brazil and South America), Olympique Lyonnais (historic multi-year champion of France), Crystal Palace Football Club (2025 FA Cup Champion), and Daring Brussels.

Fueled by our portfolio of iconic football clubs, our passionate, global audience, and our position as a preferred destination for players-our goal is to build the leading football-related enterprise on Earth. We operate on the belief that the audience of a club is always more valuable than the club, and our scalable entertainment and technology strategies are designed to maximize our total addressable market opportunity, far beyond the reach of typical football clubs. Our mission is to create value for our shareholders by being a champion for our players, our clubs, our fans and our communities, and the magnificent game of football.

Inquiries:

Eagle Football Holdings Limited
www.EagleFootball.com
press@eaglefootball.com

SOURCE: Eagle Football Holdings Limited

View the original press release on ACCESS Newswire

Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to announce the acquisition of the Wudinna Gold Project (Wudinna) from Cobra Resources PLC (Cobra) (Transaction). Wudinna is located ~200km southeast of Barton’s South Australian Tunkillia Gold Project (Tunkillia) and 200km west of Whyalla, South Australia in the north-central area of the Eyre Peninsula.

The Wudinna Gold Project is comprised of the Barns, White Tank, Clarke and Baggy Green Deposits hosting a combined JORC (2012) Mineral Resources Estimate (MRE) of 279,000oz Au (5.81Mt @ 1.5 g/t Au).

Deposit	Classification	Tonnes (Mt)	Grade (g/t Au)	Gold Ounces
Barnes	Indicated	0.44	1.3	18,000
	Inferred	2.19	1.6	116,000
White Tank	Inferred	0.33	1.5	16,000
Baggy Green	Inferred	2.12	1.4	96,000
Clarke	Inferred	0.73	1.4	33,000
Total		5.81	1.5	279,000

Table 1 – Wudinna Gold Project September 2023 JORC (2012) Mineral Resources Estimate [1]

Subject to Completion of the Transaction, and further to Barton’s other announcement of today’s date updating the Challenger JORC (2012) MRE, Barton’s total South Australian JORC Gold Mineral Resources endowment would then be 2.14Moz (78.9Mt @ 0.85 g/t Au), which is anticipated to grow further with the replacement of the estimate for Mineral Resources in the Challenger underground below the 900mRL level, which is currently underway. [2]

Completion of the Transaction is subject only to the approval of Cobra shareholders at a general meeting anticipated to be held during July 2025 (EGM).

Full details are contained in the complete announcement, which can be accessed on the ASX website, the investor section of Barton’s website, or directly by clicking here .

Commenting on the acquisition of Wudinna, Barton Managing Director Alexander Scanlon said:

“We are pleased to announce binding terms to acquire the Wudinna Gold Project, which upon Completion of the transaction will add a further 279,000oz gold to our South Australian development portfolio. The assets offer significant low-cost optionality to Barton’s long-term regional development objectives, and we will be pleased to welcome Cobra and its shareholders to Barton’s register as we steadily unlock value across our entire platform.

“We applaud South Australia for a new regulatory framework permitting the sub-division of mineral tenements. This enabled both a transaction which otherwise would not have materialised, and Wudinna’s advancement.”

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

About Barton Gold

Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 1.9Moz Au & 3.1Moz Ag JORC Mineral Resources (73.0Mt @ 0.79 g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia. *

Tarcoola Gold Project Fully permitted open pit mine with ~20koz Au within trucking distance of Barton’s Central Gawler Mill Historical goldfield with new high-grade gold-silver discovery in grades up to 83.6 g/t Au and 17,600 g/t Ag Tunkillia Gold Project 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources Optimised Scoping Study for competitive ~120kozpa gold and ~250kozpa silver bulk open pit operation Challenger Gold Project 223koz Au JORC Mineral Resources Region’s only gold processing plant (650ktpa CIP)

Competent Persons Statement & Previously Reported Information

The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

Activity	Competent Person	Membership	Status
Tarcoola Mineral Resource (Stockpiles)	Dr Andrew Fowler (Consultant)	AusIMM	Member
Tarcoola Mineral Resource (Perseverance Mine)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Tarcoola Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tarcoola Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tunkillia Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au . The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information

This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

---

[1] Refer to Cobra announcement dated 7 September 2023 (https://investors.cobraplc.com/announcements/5350232)

[2] Refer to ASX announcement dated 30 June 2025

* Refer to Barton Prospectus dated 14 May 2021 and ASX announcement dated 30 June 2025. Total Barton JORC (2012) Mineral Resources include 1,031koz Au (39.3Mt @ 0.82 g/t Au) in Indicated category and 834koz Au (33.8Mt @ 0.77 g/t Au) in Inferred category, and 3,070koz Ag (34.5Mt @ 2.80 g/t Ag) in Inferred category as a subset of Tunkillia gold JORC (2012) Mineral Resources.

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire

Priority focus on higher-grade tailings and open pit materials

ADELAIDE, AUSTRALIA / ACCESS Newswire / June 29, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to announce an updated MRE for its South Australian Challenger Gold Project (Challenger).

Challenger JORC (2012) Mineral Resources Estimate (MRE) grow to 223koz gold (9.56Mt @ 0.72 g/t Au), including 81,200oz Au contained in the existing high-grade open pit zones.

Barton has identified several potential sources of economically viable gold mineralisation adjacent to the Central Gawler Mill for use as lower-cost and lower-risk ‘Stage 1′ mill feed, and is targeting feasibility studies by the end of 2025, with initial ‘Stage 1’ operations by the end of 2026.

Barton is also evaluating the potential to reprocess (in particular) Tailings Storage Facility (TSF) 1 to extract gold as a part of Stage 1 operations. TSF1 was constructed in 2002 and decommissioned during 2009, during which time it serviced open pit mining operations from Challenger Main and the highest-grade portion of the historical U/G mine. This highest-grade mineralisation was processed last during the operation of TSF1, resulting in a higher-grade ring of mineralisation located around the periphery of TSF1 where discharge spigots were located. Examples of the consolidation of higher-grade mineralisation around the periphery of TSF1 include:

Hole ID	Interval	Including:
CHB0044	20m @ 0.70 g/t Au from 2 metres	1m @ 1.29 g/t Au from 11 metres
CHB0047	21m @ 0.66 g/t Au from 2 metres	10m @ 0.88 g/t Au from 3 metres
CHB0056	19m @ 0.66 g/t Au from 2 metres	4m @ 1.05 g/t Au from 5 metres
CHB0084	19m @ 0.75g/t Au from 2 metres	3m @ 1.06 g/t Au from 10 metres

Table – Select Challenger TSF1 higher-grade intervals from 2023 and 2025 validation drilling

Commenting on the JORC Mineral Resources update, Barton MD Alexander Scanlon said:

“As indicated to the market for the past ~24 months, we have been analysing the potential for JORC Mineral Resources in the immediate vicinity of our fully permitted Central Gawler Mill. This infrastructure is a significant leverage point for BGD’s investors, and provides the option for a shorter, lower-cost, and lower-risk pathway to operations and the re-rating of BGD to ‘producer’ status. There is significant arbitrage value in this ‘real option’.

“With the sustained upward move in gold prices, we will now look to exercise that option. During the balance of 2025 we will complete feasibility analyses to determine the preferred development pathway, with the objective to commence our initial ‘Stage 1′ operations before the end of 2026.”

Full details are contained in the complete announcement, which can be accessed on the ASX website, the investor section of Barton’s website, or directly by clicking here.

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

About Barton Gold

Barton Gold is an ASX, OTCQB and Frankfurt Stock Exchange listed Australian gold developer targeting future gold production of 150,000ozpa with 1.9Moz Au & 3.1Moz Ag JORC Mineral Resources (73.0Mt @ 0.79 g/t Au), brownfield mines, and 100% ownership of the region’s only gold mill in the renowned Gawler Craton of South Australia.*

Tarcoola Gold Project Fully permitted open pit mine with ~20koz Au within trucking distance of Barton’s Central Gawler Mill Historical goldfield with new high-grade gold-silver discovery in grades up to 83.6 g/t Au and 17,600 g/t Ag Tunkillia Gold Project 1.6Moz Au & 3.1Moz Ag JORC Mineral Resources Optimised Scoping Study for competitive ~120kozpa gold and ~250kozpa silver bulk open pit operation Challenger Gold Project 223koz Au JORC Mineral Resources Region’s only gold processing plant (650ktpa CIP)

Competent Persons Statement & Previously Reported Information

The information in this announcement that relates to the historic Exploration Results and Mineral Resources as listed in the table below is based on, and fairly represents, information and supporting documentation prepared by the Competent Person whose name appears in the same row, who is an employee of or independent consultant to the Company and is a Member or Fellow of the Australasian Institute of Mining and Metallurgy (AusIMM), Australian Institute of Geoscientists (AIG) or a Recognised Professional Organisation (RPO). Each person named in the table below has sufficient experience which is relevant to the style of mineralisation and types of deposits under consideration and to the activity which he has undertaken to quality as a Competent Person as defined in the JORC Code 2012 (JORC).

Activity	Competent Person	Membership	Status
Tarcoola Mineral Resource (Stockpiles)	Dr Andrew Fowler (Consultant)	AusIMM	Member
Tarcoola Mineral Resource (Perseverance Mine)	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Tarcoola Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tarcoola Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Exploration Results (until 15 Nov 2021)	Mr Colin Skidmore (Consultant)	AIG	Member
Tunkillia Exploration Results (after 15 Nov 2021)	Mr Marc Twining (Employee)	AusIMM	Member
Tunkillia Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow
Challenger Mineral Resource	Mr Ian Taylor (Consultant)	AusIMM	Fellow

The information relating to historic Exploration Results and Mineral Resources in this announcement is extracted from the Company’s Prospectus dated 14 May 2021 or as otherwise noted in this announcement, available from the Company’s website at www.bartongold.com.au or on the ASX website www.asx.com.au. The Company confirms that it is not aware of any new information or data that materially affects the Exploration Results and Mineral Resource information included in previous announcements and, in the case of estimates of Mineral Resources, that all material assumptions and technical parameters underpinning the estimates, and any production targets and forecast financial information derived from the production targets, continue to apply and have not materially changed. The Company confirms that the form and context in which the applicable Competent Persons’ findings are presented have not been materially modified from the previous announcements.

Cautionary Statement Regarding Forward-Looking Information

This document may contain forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “expect”, “target” and “intend” and statements than an event or result “may”, “will”, “should”, “would”, “could”, or “might” occur or be achieved and other similar expressions. Forward-looking information is subject to business, legal and economic risks and uncertainties and other factors that could cause actual results to differ materially from those contained in forward-looking statements. Such factors include, among other things, risks relating to property interests, the global economic climate, commodity prices, sovereign and legal risks, and environmental risks. Forward-looking statements are based upon estimates and opinions at the date the statements are made. Barton undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates or to update or keep current any of the information contained herein. Any estimates or projections as to events that may occur in the future (including projections of revenue, expense, net income and performance) are based upon the best judgment of Barton from information available as of the date of this document. There is no guarantee that any of these estimates or projections will be achieved. Actual results will vary from the projections and such variations may be material. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Any reliance placed by the reader on this document, or on any forward-looking statement contained in or referred to in this document will be solely at the readers own risk, and readers are cautioned not to place undue reliance on forward-looking statements due to the inherent uncertainty thereof.

View the original press release on ACCESS Newswire

VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (the “Company“) is pleased to announce that all resolutions were passed by requisite majority at its annual and special meeting of shareholders held earlier today in virtual format.

The seven incumbent directors, Julian Treger, Raffaele (Lucio) Genovese, Tom Albanese, Margot Naudie, Sharon Fay, Erez Ichilov and Robert Harward were re-elected to the Board by shareholders. The shareholders also approved the re-appointment of PricewaterhouseCoopers LLP as auditors of the Company for the ensuing year and the Company’s amended and restated omnibus equity incentive plan.

About CoTec
CoTec is a publicly traded investment issuer listed on the TSXV and the OTCQB and trades under the cymbol CTH and CTHCF respectively. CoTec is a forward-thinking resource extraction company committed to revolutionizing the global metals and minerals industry through innovative, environmentally sustainable technologies and strategic asset acquisitions. With a mission to drive the sector toward a low-carbon future, CoTec employes a dual approach: investing in disruptive mineral extraction technologies that enhance efficiency and sustainability while applying these technologies to undervalued mining assets to unlock their full potential. By focusing on recycling, waste mining, and scalable solutions, the Company accelerates the production of critical minerals, shortens development timelines, and reduces environmental impact. CoTec’s strategic model delivers low capital requirements, rapid revenue generation, and high barriers to entry, positioning it as a leading mid-tier disruptor in the commodities sector.

For more information, please visit www.cotec.ca.

For further information, please contact:
Braam Jonker – (604) 992-5600

Forward-Looking Information Cautionary Statement
Statements in this press release regarding the Company and its investments which are not historical facts are “forward-looking statements” that involve risks and uncertainties, including statements relating to management’s expectations with respect to its current and potential future investments, the value of such investments and the benefits to the Company which may be implied from such statements. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements. For further details regarding risks and uncertainties facing the Company please refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, a copy of which may be found under the Company’s SEDAR+ profile at www.sedarplus.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: CoTec Holdings Corp.

View the original press release on ACCESS Newswire